Medical Specialties > Interventional Cardiology > Platinum Stent  > Optimal Healing

Xtra Deliverability
Optimal Healing
Long Lesions
SYNERGY™ XD
 

The First DES Indicated for Use in High Bleeding Risk Patients

The SYNERGY™ XD Stent can be safely used in conjunction with shortened DAPT in patients at high risk for bleeding, based on the results from the EVOLVE Short DAPT Trial.*

Now FDA Approved - SYNERGY XD Stent, High Bleeding Risk Indication
 
EVOLVE Short DAPT Trial

EVOLVE Short DAPT Trial†1

Studying 3-month DAPT in high bleeding risk patients†1

See the Latest Data
EVOLVE Short DAPT Trial

0.2% ST

from 3-15 months

 
 

Designed for Early Healing

Trusted Everolimus Drug + Bioabsorbable Polymer

Trusted Everolimus Drug + Bioabsorbable Polymer

Unlike permanent polymer DES technology, the SYNERGY™ XD Bioabsorbable Polymer is gone shortly after the drug is completely eluted2

Learn More
Trusted Everolimus Drug + Bioabsorbable Polymer
 
 

Leading on Studying Short DAPT

SENIOR Trial

SENIOR Trial

Studying 1-month DAPT in elderly patients‡§3

Get the Latest Data
Low Crossing Profile

0% ST

from 1-12 months**

 
ASET Trial

ASET Trial

Studying 0-month DAPT in patients with chronic stable anginaࠠ4

Get More Info
0% ST at 3-months

0% ST

at 3-months

 
 

Excellent Safety & Long Term Outcomes

Kang Network Meta-Analysis

Kang Network Meta-Analysis

SYNERGY™ BP Stent ranked #1 for the lowest relative risk of def/prob ST at 1-year. §5

See the Data
Ranked #1 lowest relative risk of def/prob ST

Ranked #1

Lowest relative risk of Def/Prob ST

 
Real-World SCAAR Registry

Real-World SCAAR Registry

Lowest ST rate compared to newer generation DES despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD.*,**,6

Learn More
Real-World SCAAR Registry

Excellent Results in

Complex Patients

Lowest ST rate in statistically more complex patients

 
 

Request a rep

Fill out a quick form and one of our sales representatives will be in touch.

Request a rep
Top